Physician profile
Gregory S Beale
NPI 1497782817
$5,957.68
in general payments reported to CMS, 2019-2025
23 companies · $459 in 2025
The $459 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,335 · 2020: $956 · 2021: $969 · 2022: $1,174 · 2023: $620 · 2024: $444 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.09 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,219.34 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,051.63 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $997.95 | 2019-2025 | Ofev, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $845.59 | 2019-2025 | Dupixent |
| Genzyme Corporation | $311.92 | 2020-2025 | |
| Insmed, INC. | $297.37 | 2019-2020 | |
| Grifols USA, LLC | $256.58 | 2019-2024 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $183.58 | 2019-2020 | |
| Boston Scientific Corporation | $168.53 | 2022 | |
| Mylan Specialty L.P. | $167.68 | 2019-2021 | |
| Amgen INC. | $134.65 | 2021-2023 | Tezspire |
| Philips North America LLC | $73.82 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $67.38 | 2019-2021 | |
| Electromed, INC. | $25.58 | 2019 | |
| Novo Nordisk INC | $23.63 | 2023 | Ozempic |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21.25 | 2022 | |
| Vapotherm INC | $20.65 | 2022 | |
| United Therapeutics Corporation | $20.61 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.25 | 2019 | |
| Circassia INC. | $17.06 | 2020 | |
| Seqirus USA INC | $12.99 | 2021 | |
| Fisher & Paykel Healthcare INC | $12.57 | 2019 | |
| Inogen, INC. | $8.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Beale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.